Transplant Outcomes in Bone Marrow Failure Syndromes and Hemoglobinopathies

Margaret L. MacMillan, Mark C. Walters, Eliane Gluckman

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potential cure for most bone marrow (BM) failure syndromes and hemoglobinopathies. Over the past decade, umbilical cord blood (UCB) has been used more frequently as a stem cell source in patients who lack a suitable BM donor. Although graft failure remains a significant problem, UCB transplantation (UCBT) using the optimal conditioning regimen can be a salvage treatment for patients without a suitable BM donor and warrants evaluation in further prospective studies.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalSeminars in hematology
Issue number1
StatePublished - Jan 2010


Dive into the research topics of 'Transplant Outcomes in Bone Marrow Failure Syndromes and Hemoglobinopathies'. Together they form a unique fingerprint.

Cite this